Table 1 Baseline characteristics of patients with GISTs in the JCR and TCR databases.
From: Imatinib use for gastrointestinal stromal tumors among older patients in Japan and Taiwan
Characteristics | JCR database | TCR database | ||||||
|---|---|---|---|---|---|---|---|---|
Adjuvant | Advanced/metastatic | Adjuvant | Advanced/metastatic | |||||
(n = 232) | (n = 235) | (n = 492) | (n = 401) | |||||
Male | 108 | (46.6) | 149 | (63.4) | 259 | (52.6) | 249 | (62.1) |
Age (median [IQR], years) | 66 | (56, 73) | 66 | (57, 74) | 61 | (52, 72) | 63 | (53, 75) |
Tumor size (cm) | ||||||||
≤ 5 | 74 | (31.9) | 45 | (19.1) | 44 | (8.9) | 36 | (9.0) |
> 5– ≤ 10 | 97 | (41.8) | 79 | (33.6) | 125 | (25.4) | 67 | (16.7) |
> 10 | 47 | (20.3) | 70 | (29.8) | 98 | (19.9) | 103 | (25.7) |
Unknown | 14 | (6.0) | 41 | (17.4) | 225 | (45.7) | 195 | (48.6) |
Mitotic count | ||||||||
Low (< 5) | – | – | – | – | 112 | (22.8) | 50 | (12.5) |
High (> 5) | – | – | – | – | 241 | (49.0) | 135 | (33.7) |
Unknown | – | – | – | – | 139 | (28.3) | 216 | (53.9) |
Stage | ||||||||
I | 48 | (20.7) | 20 | (8.5) | 22 | (4.5) | 11 | (2.7) |
II | 67 | (28.9) | 29 | (12.3) | 77 | (15.7) | 26 | (6.5) |
III | 103a | (44.4)a | 54 | (23.0) | 170a | (34.5)a | 61 | (15.2) |
IV | 104 | (44.3) | 142 | (35.4) | ||||
Unknown | 14 | (6.0) | 28 | (11.9) | 223 | (45.3) | 161 | (40.1) |
Distant metastasis | ||||||||
No | 222 | (95.7) | 109 | (46.4) | 281 | (57.1) | 127 | (31.7) |
Yes | 0 | (0) | 109 | (46.4) | 0 | (0) | 141 | (35.2) |
Unknown | 10 | (4.3) | 17 | (7.2) | 211 | (42.9) | 133 | (33.2) |
Year of diagnosis | ||||||||
2012 | 46 | (19.8) | 50 | (21.3) | 164 | (33.3) | 138 | (34.4) |
2013 | 105 | (45.3) | 94 | (40.0) | 151 | (30.7) | 123 | (30.7) |
2014 | 81 | (34.9) | 91 | (38.7) | 177 | (36.0) | 140 | (34.9) |
Primary site | ||||||||
Stomach | 159 | (68.5) | 97 | (41.3) | 222 | (45.1) | 170 | (42.4) |
Small intestine/duodenum | 54 | (23.3) | 84 | (35.7) | 222 | (45.1) | 137 | (34.2) |
Others | 19 | (8.3) | 54 | (23.0) | 48 | (9.7) | 94 | (23.2) |
Treatment group | ||||||||
Continued | 109 | (47.0) | 78 | (33.3) | 53 | (10.8) | 56 | (14.0) |
Discontinued | 123 | (53.0) | 60 | (25.5) | 439 | (89.2) | 156 | (38.9) |
Switched | 0 | (0) | 97 | (41.3) | 0 | (0) | 189 | (47.1) |
Time to stop imatinib, days | ||||||||
Median, 95% CI | 788 | (361, 1040) | 541 | (416, 616) | 783.5 | (573, 993) | 685 | (580, 863) |
Starting dosage (imatinib, mg) | ||||||||
≤ 300 | 20 | (8.6) | 29 | (12.3) | 64 | (13.0) | 58 | (14.4) |
≥ 400 | 212 | (91.4) | 206 | (57.7) | 428 | (87.0) | 343 | (85.5) |
Imatinib dose over the entire treatment period (median [IQR], mg/day) | 300 | (200, 400) | 300 | (300, 400) | 400 | (400, 400) | 400 | (400, 400) |
Data duration, days | ||||||||
Mean, SD | 1051.1 | (571.6) | 1127.5 | (710.3) | 1830.1 | (551.9) | 1387.9 | (734.0) |
Median, IQR | 1008 | (593, 1443) | 1050 | (487, 1726) | 1901 | (1602.5, 2237) | 1566 | (778, 1974) |
